AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	5325	178429-62-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: solriamfetol sunosi JZP-110 ADX-N05 ARL-N05 SKL-N05	The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity and inhibits the reuptake of dopamine and norepinephrine with low potency. Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 μM) and does not inhibit serotonin reuptake (IC50 > 100 μM). Solriamfetol improves wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI). Molecular weight: 194.23 Formula: C10H14N2O2 CLOGP: 0.63 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 78.34 ALOGS: -2 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

solriamfetol
sunosi
JZP-110
ADX-N05
ARL-N05
SKL-N05

The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity and inhibits the reuptake of dopamine and norepinephrine with low potency. Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 μM) and does not inhibit serotonin reuptake (IC50 > 100 μM). Solriamfetol improves wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).

Molecular weight: 194.23
Formula: C10H14N2O2
CLOGP: 0.63
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 78.34
ALOGS: -2
ROTB: 5

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKCD,PRKDC,SIK2,SIK3,SYK,TEK,TGFBR1	35
kinase-selectivity-class	AKT1,AKT2,AKT3,AXL,CAMK2B,CAMK2D,FLT3,GRK2,MAPK1,NUAK1,PAK4,PDK4,PRKACA,PRKCD,PRKG1,ROCK1,ROCK2,SIK2,SIK3,STK33	20
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 16, 2020	EMA	Jazz Pharmaceuticals Ireland Limited
March 20, 2019	FDA	JAZZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product administration interrupted	376.43	27.19	90	3641	12402	90612314
Intentional dose omission	158.03	27.19	49	3682	17734	90606982
Anxiety	138.88	27.19	109	3622	309663	90315053
Surgery	137.28	27.19	56	3675	44831	90579885
Pre-existing condition improved	101.76	27.19	30	3701	9139	90615577
Suicidal ideation	90.54	27.19	49	3682	73806	90550910
Drug ineffective	60.47	27.19	157	3574	1384141	89240575
Drug effect less than expected	54.84	27.19	17	3714	6121	90618595
Sleep apnoea syndrome	53.14	27.19	26	3705	31721	90592995
Somnolence	52.21	27.19	53	3678	209031	90415685
Enuresis	50.58	27.19	14	3717	3400	90621316
Somnambulism	50.43	27.19	16	3715	6212	90618504
Feeling jittery	46.32	27.19	19	3712	15352	90609364
Depression	45.82	27.19	59	3672	300542	90324174
Headache	43.89	27.19	104	3627	862642	89762074
Feeling abnormal	42.83	27.19	43	3688	167192	90457524
Panic attack	39.41	27.19	20	3711	26345	90598371
Illness	36.84	27.19	29	3702	81940	90542776
Nocturia	35.47	27.19	14	3717	10241	90614475
Migraine	34.82	27.19	41	3690	190351	90434365
Bipolar disorder	33.67	27.19	13	3718	8972	90615744
Post-traumatic stress disorder	33.35	27.19	12	3719	6816	90617900
Blood pressure increased	32.04	27.19	40	3691	197177	90427539
Product dose omission issue	30.69	27.19	48	3683	291639	90333077
Feeling drunk	29.54	27.19	10	3721	4748	90619968
Postural orthostatic tachycardia syndrome	27.69	27.19	8	3723	2264	90622452
Hysterectomy	27.20	27.19	12	3719	11572	90613144

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product administration interrupted	125.05	48.12	27	820	4939	42615549
Drug ineffective	79.83	48.12	78	769	630119	41990369
Anxiety	59.71	48.12	34	813	118526	42501962

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product administration interrupted	283.20	30.70	62	2297	11230	110575710
Surgery	102.47	30.70	37	2322	41246	110545694
Intentional dose omission	93.84	30.70	29	2330	20051	110566889
Anxiety	78.12	30.70	62	2297	345016	110241924
Pre-existing condition improved	60.10	30.70	16	2343	6510	110580430
Feeling abnormal	41.89	30.70	33	2326	180678	110406262
Nocturia	37.56	30.70	14	2345	16976	110569964
Somnambulism	33.09	30.70	10	2349	6395	110580545
Suicidal ideation	32.80	30.70	22	2337	93915	110493025

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BA14	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA MoA	N0000000114	Dopamine Uptake Inhibitors
FDA EPC	N0000194049	Dopamine and Norepinephrine Reuptake Inhibitor

Related Drugs by ATC class:

N06BA Centrally acting sympathomimetics 14 drugs

amfetamine armodafinil atomoxetine dexamfetamine dexmethylphenidate fencamfamin fenetylline fenozolone lisdexamfetamine methamphetamine methylphenidate modafinil show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Narcolepsy	indication	60380001	DOID:8986
Obstructive sleep apnea syndrome	indication	78275009	DOID:0050848
Excessive daytime sleepiness - normal night sleep	indication	230489007
Monoamine oxidase inhibitor	contraindication	734595009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.22	acidic
pKa2	7.89	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	10351517	June 7, 2026	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11753368	June 7, 2026	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12209059	June 7, 2026	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	8877806	June 7, 2026	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	9604917	June 7, 2026	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	8440715	June 11, 2031	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	10512609	Sept. 5, 2037	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11998639	Sept. 5, 2037	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12390419	Sept. 5, 2037	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	10912754	June 1, 2038	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	10959976	June 1, 2038	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11648232	June 1, 2038	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS WITH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11865098	June 1, 2038	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12384743	Nov. 1, 2038	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11560354	March 6, 2039	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING A COMPOSITION COMPRISING SOLRIAMFETOL HYDROCHLORIDE AND 2-CHLOROPROPANE, WHEREIN THE COMPOSITION COMPRISES LESS THAN ABOUT 5 PPM 2‑CHLOROPROPANE
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	10940133	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11160779	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11839598	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MODERATE OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11839599	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING OBSTRUCTIVE SLEEP APNEA (OSA) AND NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11850226	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11850227	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11850228	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11857528	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11969404	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING A HISTORY OF BIPOLAR DISORDERS AND MODERATE OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11986454	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11986455	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12194016	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO OR MILD RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12318362	March 19, 2040	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MODERATE OR SEVERE RENAL IMPAIRMENT
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11771666	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11771667	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11779554	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11793776	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11872203	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	11872204	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12005036	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12036194	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12064411	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12090126	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12102609	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	12263145	Dec. 30, 2042	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 75MG BASE	SUNOSI	AXSOME MALTA	N211230	June 17, 2019	RX	TABLET	ORAL	June 17, 2026	INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	4.09	DRUG LABEL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	5.43	DRUG LABEL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR	Ki	4.85	DRUG LABEL

External reference:

ID	Source
939U7C91AI	UNII
4038551	VANDF
C4726765	UMLSCUI
CHEBI:756719	CHEBI
CHEMBL4297212	ChEMBL_ID
CHEMBL4297620	ChEMBL_ID
10130337	PUBCHEM_CID
DB14754	DRUGBANK_ID
D11315	KEGG_DRUG
10117	INN_ID
C000623308	MESH_SUPPLEMENTAL_RECORD_UI
10342	IUPHAR_LIGAND_ID
787053002	SNOMEDCT_US
787070005	SNOMEDCT_US
319330	MMSL
d09320	MMSL
017938	NDDF
2121751	RXNORM
939U7C91AI	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SUNOSI	HUMAN PRESCRIPTION DRUG LABEL	1	81968-350	TABLET, FILM COATED	75 mg	ORAL	NDA	31 sections
SUNOSI	HUMAN PRESCRIPTION DRUG LABEL	1	81968-351	TABLET, FILM COATED	150 mg	ORAL	NDA	31 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

solriamfetol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: